Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

• Published in: Journal of clinical pharmacology Vol. 61; no. 4; pp. 480 - 492
• Main Authors: Yin, Ophelia, Wagner, Andrew J., Kang, Jia, Knebel, William, Zahir, Hamim, Sande, Michiel, Tap, William D., Gelderblom, Hans, Healey, John H., Shuster, Dale, Stacchiotti, Silvia
• Format: Journal Article
• Language: English
• Published: England 01.04.2021
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aminopyridines - pharmacokinetics; Aminopyridines - therapeutic use; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Area Under Curve; Asians; Bacterial Proteins; Body Weight; Creatinine - blood; Female; Giant Cell Tumor of Tendon Sheath - drug therapy; Giant Cell Tumor of Tendon Sheath - pathology; Humans; Kidney Function Tests; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; pexidartinib; pharmacokinetics; population pharmacokinetics; Pyrroles - pharmacokinetics; Pyrroles - therapeutic use; Racial Groups; Sex Factors; Sociodemographic Factors; TGCT; Tumor Burden; Young Adult; ZAAD; pharmacokinetics; TGCT; ZAAD; PK; pexidartinib; population pharmacokinetics

Pexidartinib is a kinase inhibitor that induces tumor response and improvements in symptoms and functional outcomes in adult patients with symptomatic tenosynovial giant cell tumor (TGCT). A population pharmacokinetic (PK) model for pexidartinib and its metabolite, ZAAD, was developed, and effects o...